Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Sep 1;36(6):488-495.
doi: 10.1097/MCA.0000000000001501. Epub 2025 Jul 30.

Short-term effects of upstream high bolus dose of tirofiban in patients with ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

Amr E I Abouelnour  1 , Eman Q Mohammed, Doaa A Fouad, Aly Tohamy
Affiliations
Randomized Controlled Trial

Short-term effects of upstream high bolus dose of tirofiban in patients with ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

Amr E I Abouelnour et al. Coron Artery Dis. .

Abstract

Background: No-reflow following primary percutaneous coronary intervention (PPCI) is challenging to treat.

Objectives: The objective of this study is to evaluate the efficacy and safety of upstream high-bolus-dose tirofiban administration in ST-segment elevation myocardial infarction (STEMI) cases undergoing PPCI on top of dual antiplatelet therapy, including ticagrelor, in comparison to selective bailout administration.

Methods: This hospital-based, randomized, single-blinded prospective interventional study was conducted on 150 patients at Assiut University Heart Hospital. Patients with STEMI within 12 h after symptom onset who underwent PPCI were randomized to an upstream group ( n = 75) and a selective bailout group ( n = 75) based on the timing of the tirofiban bolus administration (25 µg/kg intravenously over 5 min).

Results: The bailout group's thrombolysis in myocardial infarction (TIMI) frame count was higher than the upstream group's, despite comparable TIMI flow and myocardial blush grade between the two groups, but only approached statistical significance [14.4 (4-36) vs 12.2 (5-55), P = 0.08]. The enzymatic infarct size tended to be lower in the upstream group. All echocardiographic findings were comparable between the two studied groups, with no significant difference ( P > 0.05). There was no significant difference between the two groups regarding clinical outcomes.

Conclusion: Compared to selective bailout administration, upstream high bolus dose of tirofiban in STEMI patients undergoing primary coronary intervention did not significantly affect angiographic outcomes, left ventricular remodeling, or function, despite smaller infarction size.

Keywords: ST-elevation myocardial infarction; no-reflow; primary percutaneous coronary intervention; tirofiban; upstream high-bolus dose.

PubMed Disclaimer

References

    1. Terkelsen CJ, Jensen LO, Tilsted HH, Thaysen P, Ravkilde J, Johnsen SP, et al. Primary percutaneous coronary intervention as a national reperfusion strategy in patients with ST-segment elevation myocardial infarction. Circ Cardiovasc Interv 2011; 4:570–576.
    1. Niccoli G, Kharbanda RK, Crea F, Banning AP. No-reflow: again prevention is better than treatment. Eur Heart J 2010; 31:2449–2455.
    1. Annibali G, Scrocca I, Aranzulla TC, Meliga E, Maiellaro F, Musumeci G. ‘No-reflow’ phenomenon: a contemporary review. J Clin Med 2022; 11:2233.
    1. Balghith MA. High bolus tirofiban vs abciximab in acute STEMI patients undergoing primary PCI-The Tamip study. Heart Views 2012; 13:85–90.
    1. Kaymaz C, Keleş N, Özdemir N, Tanboğa IH, Demircan HC, Can MM, et al. The effects of tirofiban infusion on clinical and angiographic outcomes of patients with STEMI undergoing primary PCI. Anatol J Cardiol 2015; 15:899–906.

Publication types

MeSH terms

LinkOut - more resources